Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $10.14 Average Target Price from Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $10.14.

Several analysts recently weighed in on AQST shares. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer began coverage on Aquestive Therapeutics in a research note on Monday, June 2nd. They set an "outperform" rating and a $7.00 target price for the company.

Aquestive Therapeutics Trading Down 1.4%

Shares of NASDAQ:AQST traded down $0.06 during trading on Wednesday, hitting $3.96. 220,482 shares of the company's stock traded hands, compared to its average volume of 1,494,524. Aquestive Therapeutics has a 52 week low of $2.12 and a 52 week high of $5.80. The company has a market cap of $392.85 million, a price-to-earnings ratio of -6.69 and a beta of 1.97. The company has a 50-day moving average price of $3.06 and a 200-day moving average price of $3.01.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. On average, analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Summit Wealth & Retirement Planning Inc. purchased a new position in shares of Aquestive Therapeutics in the 1st quarter worth $29,000. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics in the 1st quarter worth $31,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Aquestive Therapeutics during the first quarter valued at about $33,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Aquestive Therapeutics during the fourth quarter valued at about $44,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Aquestive Therapeutics during the fourth quarter valued at about $57,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.